Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Fexuprazan on Clopidogrel PD in Healthy Subjects
NCT05574374Phase 1Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Sep 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fexuprazan in gastroesophageal reflux disease (GERD) (3 cohorts), sponsored by Daewoong Pharmaceutical. Primary endpoints: Maximum Effect up to 50 days and Area Under the Effect Curve from time 0 to 24 hours. Started Sep 2022; status: completed.
02
Drugs
fexuprazan
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT05574374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05574374.